Optimal usage of radium-223 in metastatic castration-resistant prostate cancer

被引：14

作者：

Cha, Tai-Lung ^{[1
]}

Wu, Tony Tong-Lin ^{[2
]}

Vogelzang, Nicholas John ^{[3
,13
]}

Huang, Chao-Yuan ^{[4
]}

Huang, Shu-Pin ^{[5
]}

Lin, Chia-Chi ^{[6
]}

Ou, Yen-Chuan ^{[7
]}

Pang, See-Tong ^{[8
]}

Shen, Daniel Heung-Yuan ^{[9
]}

Wu, Wen-Jeng ^{[10
]}

Chang, Wayne Yen-Hwa ^{[11
,12
]}

机构：

[1] Natl Def Med Ctr, Div Urol, Dept Surg, Triserv Gen Hosp, Taipei, Taiwan

[2] Kaohsiung Vet Gen Hosp, Div Urol, Dept Surg, Kaohsiung, Taiwan

[3] Univ Nevada, Sch Med, Med Oncol Comprehens Canc Ctr Nevada, Las Vegas, NV 89154 USA

[4] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan

[5] Kaohsiung Med Univ, Dept Urol, Chung Ho Mem Hosp, Kaohsiung, Taiwan

[6] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[7] Taichung Vet Gen Hosp, Div Urol, Dept Surg, Taichung, Taiwan

[8] Chang Gung Mem Hosp, Div Urol, Dept Surg, Linkou, Taiwan

[9] Natl Def Med Ctr, Dept Nucl Med, Triserv Gen Hosp, Taipei, Taiwan

[10] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Urol, Chung Ho Mem Hosp, Kaohsiung, Taiwan

[11] Taipei Vet Gen Hosp, Div Gen Urol, Dept Urol, Taipei, Taiwan

[12] Natl Yang Ming Univ, Dept Urol, Sch Med, Taipei, Taiwan

[13] Comprehens Canc Ctr Nevada, 3730 S Eastern Ave, Las Vegas, NV 89169 USA

来源：

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | 2017年 / 116卷 / 11期

关键词：

Radium chloride Ra 223; Radiopharmaceuti-cals; PAINFUL BONE METASTASES; DOUBLE-BLIND; CLINICAL-EXPERIENCE; PHASE-III; CHLORIDE; SURVIVAL; THERAPY; MULTICENTER; PALLIATION; DICHLORIDE;

D O I：

10.1016/j.jfma.2017.04.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Radium-223 is a first-in-class alpha-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase III trial ALSYMPCA, radium-223 significantly increased overall survival (OS), compared with placebo (median 14.9 vs 11.3 months; hazard ratio 0.70; 95% CI 0.58-0.83; p < 0.001), in patients with mCRPC and symptomatic bone metastasese-with a comparable safety profile.

引用

页码：825 / 836

页数：12

共 50 条

[41] Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223
Odo, Ugochukwu
Vasudevamurthy, Ashwin K.
Sartor, Oliver
CLINICAL GENITOURINARY CANCER, 2017, 15 (03) : E501 - E502
[42] Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice
Morgan, Scott C.
JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2019, 50 (04) : S26 - S30
[43] Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer
Wong, William W.
Anderson, Eric M.
Mohammadi, Homan
Daniels, Thomas B.
Schild, Steve E.
Keole, Sameer R.
Choo, C. Richard
Tzou, Katherine S.
Bryce, Alan H.
Ho, Thai H.
Quevedo, Fernando J.
Vora, Sujay A.
CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E969 - E975
[44] Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer
Picciotto, Maria
Franchina, Tindara
Russo, Alessandro
Ricciardi, Giuseppina Rosaria Rita
Provazza, Giusy
Sava, Serena
Baldari, Sergio
Caffo, Orazio
Adamo, Vincenzo
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (09) : 899 - 908
[45] Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients
Marie Øbro Fosbøl
Peter Meidahl Petersen
Gedske Daugaard
Søren Holm
Andreas Kjaer
Jann Mortensen
Annals of Nuclear Medicine, 2018, 32 : 16 - 21
[46] Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients
Fosbol, Marie Obro
Petersen, Peter Meidahl
Daugaard, Gedske
Holm, Soren
Kjaer, Andreas
Mortensen, Jann
ANNALS OF NUCLEAR MEDICINE, 2018, 32 (01) : 16 - 21
[47] Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Nilsson, Sten
CURRENT ONCOLOGY REPORTS, 2016, 18 (02) : 1 - 12
[48] Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Sten Nilsson
Current Oncology Reports, 2016, 18
[49] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
Hijab, A.
Tunariu, N.
Tovey, H.
Alonzi, R.
Tree, A.
Staffurth, J.
Blackledge, M.
Padhani, A. R.
Stidwill, H.
Finch, J.
Chatfield, P.
Perry, S.
Koh, D-M.
Hall, E.
Parker, C.
ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
[50] Radium-223 Chloride A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
Pinto, Alvaro
Cruz, Patricia
DRUGS IN R&D, 2012, 12 (04) : 227 - 233

← 1 2 3 4 5 →